Weekly Research Analysts’ Ratings Changes for CASI Pharmaceuticals (CASI)

CASI Pharmaceuticals (NASDAQ: CASI) recently received a number of ratings updates from brokerages and research firms:

  • 5/22/2022 – CASI Pharmaceuticals is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 5/14/2022 – CASI Pharmaceuticals is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 5/13/2022 – CASI Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company’s products present antiangiogenic solutions to cancer, cardiovascular disease, and macular degeneration. CASI Pharmaceuticals Inc., formerly known as EntreMed, Inc., is headquartered in Rockville, Maryland. “
  • 5/13/2022 – CASI Pharmaceuticals had its price target lowered by analysts at HC Wainwright from $4.00 to $3.00.
  • 5/6/2022 – CASI Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company’s products present antiangiogenic solutions to cancer, cardiovascular disease, and macular degeneration. CASI Pharmaceuticals Inc., formerly known as EntreMed, Inc., is headquartered in Rockville, Maryland. “
  • 5/6/2022 – CASI Pharmaceuticals is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 4/21/2022 – CASI Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company’s products present antiangiogenic solutions to cancer, cardiovascular disease, and macular degeneration. CASI Pharmaceuticals Inc., formerly known as EntreMed, Inc., is headquartered in Rockville, Maryland. “
  • 4/15/2022 – CASI Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company’s products present antiangiogenic solutions to cancer, cardiovascular disease, and macular degeneration. CASI Pharmaceuticals Inc., formerly known as EntreMed, Inc., is headquartered in Rockville, Maryland. “
  • 4/8/2022 – CASI Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company’s products present antiangiogenic solutions to cancer, cardiovascular disease, and macular degeneration. CASI Pharmaceuticals Inc., formerly known as EntreMed, Inc., is headquartered in Rockville, Maryland. “
  • 3/31/2022 – CASI Pharmaceuticals is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 3/30/2022 – CASI Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company’s products present antiangiogenic solutions to cancer, cardiovascular disease, and macular degeneration. CASI Pharmaceuticals Inc., formerly known as EntreMed, Inc., is headquartered in Rockville, Maryland. “

NASDAQ:CASI opened at $0.48 on Thursday. CASI Pharmaceuticals, Inc. has a one year low of $0.31 and a one year high of $1.78. The business’s 50-day simple moving average is $0.58 and its 200 day simple moving average is $0.74. The stock has a market cap of $65.31 million, a price-to-earnings ratio of -2.18 and a beta of 0.66.

CASI Pharmaceuticals (NASDAQ:CASIGet Rating) last announced its quarterly earnings data on Thursday, May 12th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.03. CASI Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 93.65%. During the same period last year, the company earned ($0.11) earnings per share. As a group, equities research analysts expect that CASI Pharmaceuticals, Inc. will post -0.22 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP bought a new stake in CASI Pharmaceuticals in the first quarter valued at about $44,000. UBS Group AG increased its holdings in CASI Pharmaceuticals by 493.1% in the third quarter. UBS Group AG now owns 26,715 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 22,211 shares during the last quarter. Citadel Advisors LLC bought a new stake in CASI Pharmaceuticals in the third quarter valued at about $35,000. Morgan Stanley increased its holdings in CASI Pharmaceuticals by 781.2% in the second quarter. Morgan Stanley now owns 43,285 shares of the biotechnology company’s stock valued at $68,000 after buying an additional 38,373 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of CASI Pharmaceuticals during the third quarter valued at approximately $72,000. 39.51% of the stock is owned by hedge funds and other institutional investors.

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.

Read More

Receive News & Ratings for CASI Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.